ACELYRIN, INC. (SLRN)
(Delayed Data from NSDQ)
$4.98 USD
+0.07 (1.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SLRN 4.98 +0.07(1.43%)
Will SLRN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SLRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLRN
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%
SLRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SLRN
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
UCB gets expanded FDA approval for psoriasis drug Bimzelx
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
Acelyrin spikes as late-stage data for lead asset selected for medical event
Acelyrin announces positive results from Phase 3 trial of izokibep